IU receives $2M gift supporting lung, pancreatic cancer research

American Lung Association invites applications for grants to transform lung health

The American Lung Association in the District announced the opening of its 2026-2027 Research Awards and Grants cycle. Researchers across disciplines are encouraged to apply.

September 05, 2025

Vol.51 No.32

Clinical Roundup

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

ELI-002 2P, an off-the-shelf cancer vaccine, can trigger powerful and lasting immune responses, and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, according to a study published in Nature Medicine.

September 05, 2025

Vol.51 No.32

Clinical Roundup

Blocking macropinocytosis changes TME, allows for more effective treatment, preclinical study shows

Blocking macropinocytosis reshapes the tumor microenvironment to be less fibrous and to allow more access to immune cells, according to a preclinical study of pancreatic tumors conducted by scientists at Sanford Burnham Prebys, an NCI-designated Cancer Center.

August 01, 2025

Vol.51 No.30

In Brief

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

The Stephenson Global Pancreatic Cancer Research Institute and its partner, City of Hope, announced the six inaugural recipients of the Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, early detection, and treatment of pancreatic cancer (The Cancer Letter, Sept. 17, 2024).

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

IU receives $2M gift supporting lung, pancreatic cancer research

YOU MAY BE INTERESTED IN

American Lung Association invites applications for grants to transform lung health

Off-the-shelf cancer vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

Blocking macropinocytosis changes TME, allows for more effective treatment, preclinical study shows

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Renew today!

Subscriber content

Never miss an issue!

Login